Top 10 Selegiline (Eldepryl) Generic Manufacturers in Israel
The pharmaceutical market in Israel has demonstrated significant growth, particularly in the production and distribution of generic medications. As of 2022, Israel’s pharmaceutical industry reached an estimated market size of around $2.5 billion, with generics accounting for approximately 30% of this value. The demand for antidepressants and neuroprotective agents, such as Selegiline (Eldepryl), has been significantly influenced by the increasing prevalence of neurodegenerative diseases. This report outlines the top 10 generic manufacturers of Selegiline in Israel, highlighting their market performance and relevance in the industry.
1. Teva Pharmaceutical Industries
Teva is the largest generic manufacturer in Israel and holds a substantial market share in the global pharmaceutical sector. In 2021, Teva generated revenues of approximately $16.9 billion, with their generics segment contributing significantly. Teva’s Selegiline production facilities are known for high-quality standards, making it a trusted name in the industry.
2. Taro Pharmaceutical Industries
Taro Pharmaceutical is a major player in the Israeli pharmaceutical market, with an annual revenue exceeding $1 billion. The company has a diverse portfolio, including generic medications like Selegiline. Taro has been expanding its production capabilities, focusing on enhancing the availability of its generic products.
3. Israel Pharmaceuticals
Israel Pharmaceuticals specializes in the development and manufacturing of generic medications, contributing around $200 million to the market annually. Their focus on neuropharmacology has positioned them as a key manufacturer of Selegiline, emphasizing quality and compliance with international standards.
4. Perrigo Company
Perrigo operates in Israel and has a strong foothold in the generics market, with revenues of approximately $1.5 billion in recent years. The company is recognized for its high-quality generics, including Selegiline, and has a commitment to expanding its therapeutic offerings in the central nervous system (CNS) category.
5. Kamada Ltd.
Kamada is a biopharmaceutical company with annual revenues nearing $100 million, focusing on specialty pharmaceuticals, including generics. Although primarily known for its specialty products, Kamada has ventured into the production of Selegiline, addressing the needs of patients with Parkinson’s disease and depression.
6. Dexcel Pharma
Dexcel Pharma has been a significant contributor to the Israeli generic market with revenues around $300 million. The company specializes in oral and injectable dosage forms, including Selegiline, and emphasizes research and development to enhance their product portfolio.
7. BiondVax Pharmaceuticals
BiondVax is recognized in the pharmaceutical landscape for its innovative approaches. With revenues of approximately $50 million, they have recently entered the generic market, including Selegiline, to diversify their offerings and meet growing patient demands.
8. Abic Marketing
Abic is a subsidiary of Teva and focuses on the marketing of generic pharmaceuticals. Their contribution to the Selegiline market is significant, with an estimated market share of 5% in Israel’s generic sector. Abic is known for its effective distribution strategies and partnerships.
9. Makhteshim Agan Industries (ADAMA)
ADAMA, primarily known for agricultural products, has entered the pharmaceutical space recently, generating around $1 billion in revenue. Their commitment to quality has allowed them to manufacture Selegiline, targeting both local and export markets.
10. Promedico
Promedico is a smaller but emerging player in the Israeli pharmaceutical market, with revenues around $30 million. They focus on providing quality generics, including Selegiline, and are making strides in expanding their distribution networks to enhance accessibility.
Insights
The Israeli pharmaceutical market for generics, particularly Selegiline, is poised for growth, driven by increasing demand for affordable medication amidst rising healthcare costs. With Israel’s strong emphasis on R&D and quality assurance, generic manufacturers are well-positioned to capitalize on the growing global demand. As of 2023, the global generic drug market is projected to reach $500 billion, with a compound annual growth rate (CAGR) of 7.5%. Manufacturers like Teva and Taro are likely to lead this growth, leveraging their extensive distribution networks and commitment to innovation in generic formulations.
Related Analysis: View Previous Industry Report
